Mink Therapeutics (INKT) Q4 2024 earnings summary

Executive summary

• Achieved significant clinical and manufacturing progress in 2024, advancing scalable allogeneic iNKT cell therapies for solid tumors and immune-driven diseases, and expanding partnerships, including a collaboration with Autonomous Therapeutics for RNA-iNKT therapies targeting metastatic tumors.

• Strengthened leadership with the addition of Dr. Robert Kadlec to the board and prioritized externally funded clinical trials.

Financial highlights

• Ended 2024 with a cash balance of $4.6 million, down from $5.7 million at year-end 2023.

• Net loss for 2024 was $10.8 million ($2.86 per share), improved from $22.5 million ($6.54 per share) in 2023.

• Cash used in operations was $9.6 million for 2024, down from $15.8 million in 2023.

Outlook and guidance

• Plans to deliver additional clinical data from the gastric cancer trial, advance the GVHD study into patient dosing, and file INDs for next-generation iNKT programs in 2025.

• Cash runway projected through the end of 2025, with ongoing efforts to secure non-dilutive and partnership funding.

• Late-stage trials for AgenT-797 in ARDS are designed and planned for regulatory discussions.